Related Experiment Video
Updated: Sep 12, 2025
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
Incidence of Vaginal Intraepithelial Neoplasia After Hysterectomy for Cervical Cancer or Cervical Intraepithelial
Rui Li1, Li-Fei Sun, Rui-Zhe Li
1Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, the Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, and the Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.
Objective:
To investigate the incidence of vaginal intraepithelial neoplasia (VAIN) 1+ in patients after hysterectomy for cervical intraepithelial neoplasia (CIN) or cervical cancer.
Data Sources:
A systematic search was conducted in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials from inception to January 2025.
Methods Of Study Selection:
We identified 7,234 studies, 48 of which were included in the meta-analysis. The primary outcome was the incidence of pathologically confirmed VAIN 1+ (VAIN 1, 2, or 3 or vaginal cancer) in patients after hysterectomy for CIN or cervical cancer; the secondary outcome was the clinicopathologic characteristics of these patients. Single-proportion meta-analysis was performed to estimate the incidence and 95% CIs of VAIN 1+.
Tabulation, Integration, And Results:
A total of 18,959 patients who underwent hysterectomy for CIN or cervical cancer were included. The overall pooled incidence of VAIN 1+ was 2.7% (95% CI, 1.8-3.7%). The incidences of VAIN and vaginal cancer were 2.7% (95% CI, 1.7-3.7%) and 0.3‰ (95% CI, 0.0-1.0‰), respectively. The incidence of VAIN increased gradually in more recent studies compared with studies published before 2000.
Conclusion:
Nearly 3 of every 100 women develop VAIN 1+ after hysterectomy for CIN or cervical cancer. The rate of vaginal dysplasia has significantly increased over time.
Systematic Review Registration:
PROSPERO, CRD42023433781.
More Related Videos
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
03:30Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy
Published on: October 25, 2024
